Company: MVIS
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021931
Chunk: 9

Company: MICROVISION, INC.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 2
Chunk 9
---
 on our current operating plan, we anticipate that we have sufficient cash and
cash equivalents to fund our operations for at least the next 12 months.

Operating
activities

Cash
used in operating activities totaled $43.3 million during the nine months ended September 30, 2025 compared to cash used in
operating activities of $53.5 million during the same period in 2024. Cash used in operating activities resulted primarily from cash
used to fund our net loss, after adjusting for non-cash charges such as share-based compensation, intangible impairment expense,
depreciation and amortization charges, unrealized gains and losses, and changes in operating assets and liabilities. The changes in
cash used in operating activities were primarily attributed to decreased operating expenses related to personnel. We expect to make
minimum payments to our contract manufacturing partner in connection with the production of MOVIA L sensor inventory of
approximately $2.0 million during the remainder of 2025 and 2026 in line with agreed-upon deliveries.

Investing
activities

During
the nine months ended September 30, 2025, net cash used in investing activities was $6.6 million compared to net cash used in investing
activities of $3.8 million during the same period in 2024. During the nine months ended September 30, 2025, we purchased short-term investment
securities totaling $32.9 million and sold short-term investment securities totaling $26.7 million, compared to purchases of $25.6 million
and sales of $28.3 million in the same period of 2024. During the nine months ended September 30,
2024, we made payments totaling $6.3 million related to the acquisition of Ibeo assets.

Financing
activities

Net
cash provided by financing activities totaled $67.8 million during the nine months ended September 30, 2025, compared to net cash provided
by financing activities of $26.2 million during the same period of 2024. During the nine months ended September 30, 2025, we repaid $5.0 million principal on our outstanding note payable plus a
10% repayment premium. Net proceeds from issuance of common stock and warrants were $73.3 million during
nine months ended September 30, 2025 compared to $26.1 million during the same period in 2024. 

The
following is a list of our financing activities during 2025 and